Last update 15 Dec 2025

Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)

Overview

Basic Info

Drug Type
Stem cell therapy
Synonyms-
Target-
Action-
Mechanism-
Therapeutic Areas
Congenital DisordersEndocrinology and Metabolic DiseaseHemic and Lymphatic Diseases+ [1]
Active Indication-
Inactive Indication
Beta-ThalassemiaFanconi Anemia
Originator Organization
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
Active Organization-
Inactive Organization
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
License Organization-
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)
ChiCTR2000031648
/ Not yet recruitingEarly Phase 1IIT
Clinical study for the efficacy and safety of gene-corrected autologous hematopoietic stem cell transplantation in the treatment of severe β-thalassemia
ChiCTR2000031647
/ Not yet recruitingEarly Phase 1IIT
Clinical study for the effectiveness and safety of gene-corrected autologous hematopoietic stem cell transplantation in the treatment of hemophilia B
NCT03351868
/ Unknown statusNot ApplicableIIT
Gene Transfer for Fanconi Anemia Using a Self-inactivating Lentiviral Vector
100 Clinical Results associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Translational Medicine associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Patents (Medical) associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Deals associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fanconi AnemiaPhase 2
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
01 Dec 2017
Beta-ThalassemiaClinical
China
Shenzhen Geno-Immune Medical InstituteShenzhen Geno-Immune Medical Institute
01 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free